SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is capturing investor attention following a series of strategic partnership expansions with U.S. national laboratories and the announcement of an upcoming Analyst Day at the NYSE. Community sentiment remains focused on the company's neutral-atom technology and perceived valuation gap relative to other quantum players, with many investors actively debating the stock's long-term potential as a defense and infrastructure play.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing intense market volatility and community scrutiny as investors react to a jury finding the CEO liable for defrauding shareholders during a past takeover, alongside concerns regarding softening EV demand and aggressive infrastructure spending. Community sentiment is deeply polarized, with active debates centered on the company's long-term pivot to AI and robotics versus mounting regulatory challenges and the financial implications of the current geopolitical climate.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community debate the stock's volatility alongside the President's recent high-stakes ultimatum regarding Iranian power infrastructure. Sentiment remains deeply polarized, with active discussions centering on the company's financial health, the impact of escalating geopolitical tensions on energy markets, and the broader political controversy surrounding the administration's policy decisions.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors react to strong earnings results, including 18 consecutive beat-and-raise quarters and a strategic shift to GAAP profitability. The community is actively debating the stock's valuation, contrasting its robust growth and AI-driven martech platform against broader software sector volatility and lingering short interest.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive (DRV) is gaining momentum as traders highlight its technical strength, recent consolidation, and the anticipation of treasury buybacks. The community is actively discussing its potential for a breakout, bolstered by strategic partnerships and its role in building derivatives infrastructure on Ethereum.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors pivot toward the company as a key beneficiary of the enterprise AI infrastructure build-out, especially following significant volatility and regulatory scrutiny surrounding its competitor, Supermicro. Community sentiment is largely focused on the company's robust AI server backlog and expectations that it will capture substantial market share, with many participants viewing it as a safer, more stable play for capturing long-term value in the sector.

Polygon

Polygon is currently trending as investors debate the potential rebrand back to the MATIC ticker while analyzing its pivot toward regulated stablecoin payments and institutional adoption. Community sentiment remains polarized, with many users expressing frustration over recent price performance while others highlight significant network activity and the deflationary impact of token burns.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest record quarterly bookings and an upbeat 2026 outlook, fueled by relentless demand for EUV lithography machines essential to the global AI hardware arms race. While the community is actively debating the stock's premium valuation and potential for a share split, sentiment remains anchored by the company's unassailable monopoly and long-term role as the backbone of the semiconductor supply chain.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401JK community is driving momentum through a grassroots campaign that uses memes and "IRL raids" to mock traditional retirement systems, positioning the token as a rebellious alternative to a perceived broken financial model. Supporters are actively engaging on social platforms to highlight the project's educational resources and staking mechanisms, maintaining high conviction that their movement offers a viable path to financial independence.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco Corp is trending significantly higher following a blockbuster partnership with the U.S. government and Brookfield Asset Management to invest $80 billion in deploying Westinghouse nuclear reactors. Investors are cheering the move as a major validation of nuclear energy's role in powering AI and data center infrastructure, leading to heavy call-buying volume and renewed optimism for the sector's long-term capacity buildout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 'Lithium in Brain' Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital Alzamend Neuro Initiates...

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?

Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 'Lithium in Brain' Study Conducted at Massachusetts General Hospital Alzamend Neuro Announces Completion of...

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.read more...

Shares of Alzamend Neuro, Inc. (ALZN) soared 82% on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.alzamend.com/news-events/press-releases/detail/93/alzamend-neuro-announces-dosing-of-first-patient-in-its">announced</a> the dosing of the first patient in its first Phase II clinical study of AL001 in healthy human subjects.AL001 is a novel lithium-delivery system that has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.The system is designed to favorably distribute lithium in the brain, resulting in lower exposure of other body organs and an improved safety profile compared to currently marketed lithium salts.The study in healthy human subjects is expected to help the company determine the best path forward in Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder patients by demonstrating AL001’s targeted effectiveness and reduced systemic side effects, the company said.Lithium is known for its efficacy as a first-line therapy for manic episodes and maintenance in bipolar disorder.However, current lithium salts require regular lithium therapeutic drug monitoring of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events that could affect the kidneys and thyroid.Alzamend said that AL001 would potentially eliminate the need for lithium therapeutic drug monitoring. The company’s previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, it addedAlzamend CEO Stephan Jackman said that the company is expected to announce data from the new study before the end of the year.“This advancement stands to potentially enhance the lives of over 43 million Americans suffering from Alzheimer’s, BD, MDD, and PTSD,” he added.On Stocktwits, retail sentiment around Alzamend jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume soared from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_1_18_03_PM_png_9982df14f5.webp" alt="ALZN's Sentiment Meter and Message Volume as of 1:18 p.m. ET on May 29, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>ALZN's Sentiment Meter and Message Volume as of 1:18 p.m. ET on May 29, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ALZN">ALZN stock</a> is down by about 44% this year and by about 88% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/uber-stock-falls-after-tesla-s-june-12-robotaxi-launch-report/ch0AH7SRbtU">Uber Stock Falls After Tesla’s June 12 Robotaxi Launch Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled

AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.

Equity

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

ALZN
Alzamend Neuro Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALZN News

ALZNAlzamend Neuro Inc